Health & bio

Daraxonrasib Doubles One-Year Pancreatic Cancer Survival

The RAS(ON) inhibitor daraxonrasib achieved roughly double the one-year survival rate in advanced pancreatic cancer Phase 1/2 data—major oncology news dominating mid-April coverage (Northwestern, NatGeo, Dana-Farber).

Primary sources · 2
Northwestern releaseDana-Farber release
← View the full 2026-04-11 (Sat) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →